CAMP and neoplasm: Based on these findings, we posit that the NE/CAMP+aPD‐1 combination induces potent and long‐term systemic immune activation, resulting in a superior anti‐tumor effect compared with other groups and induces complete regression of subcutaneously implanted GL261.